VFEND 200 MG POWDER FOR SOLUTION FOR INFUSION

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

VORICONAZOLE 200 MG/VIAL

Disponible desde:

PFIZER PHARMACEUTICALS ISRAEL LTD

Código ATC:

J02AC03

formulario farmacéutico:

POWDER FOR SOLUTION FOR INFUSION

Vía de administración:

I.V

Fabricado por:

PFIZER PGM, FRANCE

Grupo terapéutico:

VORICONAZOLE

indicaciones terapéuticas:

Treatment of : - invasive aspergillosis fluconazole-resistant serious invasive Candida infections (including C. krusei), - serious fungal infections caused by scedosporium spp. and fusarium spp.Vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. Treatment of candidemia in non neutropenic patients.

Fecha de autorización:

2012-10-01